Gray Market Peptides: So Much Hype, So Little Data The Pharmacology of Longevity: Peptide Edition (Part 1) Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and